Cardiovascular events and mortality in chronic kidney disease (stages I-IV);Eventos cardiovasculares y mortalidad en pacientes con enfermedad renal crónica (estadios I a IV)

Nefrologia

Volumn 33, Issue 4, 2013, Pages 539-545

  Quiroga, Borja ^a   Verdalles, Úrsula ^a   Reque, Javier ^a   De Vinuesa, Soledad García ^a   Goicoechea, Marian ^a   Luño, José ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Cardiovascular disease; Chronic kidney disease (CKD); Diabetes mellitus; Proteinuria; Troponin T

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DISEASE COURSE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY;

AGED; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84882945239     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2013.May.11895     Document Type: Article

References (38)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296-305.
2. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004;65(6):2380-9.
3. Quiroga B, Marin C, Goicoechea M, Reque J, Luño J. Inflammatory biomarkers in chronic kidney disease: a review. Recent Pat Biomark 2012;2:131-8.
4. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39 (2 Supp 1):S1-266.
5. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110(5):588-636.
6. Documento de consenso sobre la Enfermedad Renal Crónica. Available at:http://www.semg.es/doc/documentos_SEMG/Doc_consenso_final_13 1212.pdf
7. Quiroga B, Goicoechea M, García de Vinuesa S, Verde E, Verdalles U, Yuste C, et al. Cardiac markers in different degrees of chronic kidney disease: influence of inflammation and previous heart disease. Med Clin (Barc) 2012;139(3):98-102.
8. DeFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003;290(3):353-9.
9. Scotece M, Conde J, Gómez R, López V, Pino J, Gonzàlez A, et al. Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. Mediators Inflamm 2012;2012:125458.
10. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359(17):1811-21.
11. Goicoechea M, Quiroga B, García de Vinuesa S, Verdalles U, Reque J, Panizo N, et al. Intraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease. Ren Fail 2012;34(8):1002-9.
12. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5(8):1388-93.
13. Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22(2):198-203.
14. Weir MR. Recognizing the link between chronic kidney disease and cardiovascular disease. Am J Manag Care 2011;17 Suppl 15:S396-402.
15. Jaradat MI, Molitoris BA. Cardiovascular disease in patients with chronic kidney disease. Semin Nephrol 2002;22(6):459-73.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
17. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004 Aug.
18. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003;139(2):137-47.
19. Coresh J, Longenecker JC, Miller ER 3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998;9(12 Suppl):S24-30.
20. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(12 Suppl):S16-23.
21. Bae EH, Lim SY, Cho KH, Choi JS, Kim CS, Park JW, et al. GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry. Am J Kidney Dis 2012;59(6):795-802.
22. Kondo T, Osugi S, Shimokata K, Honjo H, Okumura N, Matsudaira K, et al. Cardiovascular events increased at normal and high-normal blood pressure in young and middle-aged Japanese male smokers but not in nonsmokers. J Hypertens 2013;31(2):263-70.
23. Rowland ML, Fulwood R. Coronary heart disease risk factor trends in blacks between the first and second National Health and Nutrition Examination Surveys, United States, 1971-1980. Am Heart J 1984;108(3 Pt 2):771-9.
24. Ojeda R, Aljama PA. Chronic microinflammation and endothelial damage in uremia. Nefrologia 2008;28(6):583-6.
25. Cases A, Vera M, López Gómez JM. Cardiovascular risk in patients with chronic renal failure. Patients in renal replacement therapy. Nefrologia 2002;22 Suppl 1:68-74.
26. Merino A, Nogueras S, Buendía P, Ojeda R, Carracedo J, Ramirez-Chamond R, et al. Microinflammation and endothelial damage in hemodialysis. Contrib Nephrol 2008;161:83-8.
27. Robles NR, Felix FJ, Fernandez-Berges D, Perez-Castàn JF, Zaro MJ, Lozano L, et al. Cross-sectional survey of the prevalence of reduced estimated glomerular filtration rate, albuminuria and cardiovascular risk in a native Spanish population. J Nephrol 2012 Oct 15:0.
28. Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, et al. Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 2007;25(4):871-6.
29. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular Enviado a Revisar: 29 Dic. 2012 Aceptado el: 21 May. 2013 outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9.
30. Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Viitasalo M, et al. Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. Am J Hypertens 2008;21(3):273-9.
31. Abbas NA, John RI, Webb MC, Kempson ME, Potter AN, Price CP, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem 2005;51:2059-66.
32. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002;106:2941-5.
33. Wang AY, Lam CW, Wang M, Chan IH, Goggins WB, Yu CM, et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. Clin Chem 2007;53(5):882-9.
34. Lou QL, Ouyang XJ, Gu LB, Mo YZ, Ma R, Nan J, et al. Chronic kidney disease and associated cardiovascular risk factors in chinese with type 2 diabetes. Diabetes Metab J 2012;36(6):433-42.
35. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012;157(9):601-10.
36. Barkoudah E, Skali H, Uno H, Solomon SD, Pfeffer MA. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc 2012;1(1):8-15.
37. Chrysant SG, Chrysant GS. Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. Am J Cardiol 2010;106(6):825-9.
38. Chen CY, Yoshida A, Asakura M, Hasegawa T, Takahama H, Amaki M, et al. Serum blood urea nitrogen and plasma brain natriuretic Peptide and low diastolic blood pressure predict cardiovascular morbidity and mortality following discharge in acute decompensated heart failure patients. Circ J 2012;76(10):2372-9.